Key result
Urban residence compared to rural residence showed no significant difference in the overall use of any antiarrhythmic therapy among patients with incident atrial fibrillation (aIRR 1.01, 95% CI 0.99-1.03), suggesting no large geographic inequity in rhythm control strategy utilization.
Why the study?
Rural-urban disparities have been reported in healthcare access, utilization, and quality, but whether antiarrhythmic therapy use in AF differs by rural versus urban residence was unclear.
Does urban residence influence the likelihood of receiving antiarrhythmic therapies in patients with incident atrial fibrillation?
Cohort (n=177,529)
Yes
Does urban residence influence the likelihood of receiving antiarrhythmic therapies in patients with incident atrial fibrillation?
This nationwide Finnish study demonstrates that there are no major disparities in the overall utilization of rhythm control strategies for atrial fibrillation between rural and urban areas, though urban patients receive slightly more antiarrhythmic drugs.
Answers are grounded in this paper and cite their sources.
No substantial rural-urban disparity in antiarrhythmic therapy for incident AF; supports equitable access in Finland but leaves open generalizability elsewhere.
Background: Rural–urban disparities have been reported in the access, utilization, and quality of healthcare. We aimed to assess whether use of antiarrhythmic therapies (AATs) in patients with atrial fibrillation (AF) differs between those with rural and urban residence. Methods: The registry-based FinACAF cohort covers all patients with AF from all levels of care in Finland. Patients were divided into rural and urban categories and into urbanization degree tertiles based on their municipality of residence at the time of AF diagnosis. The primary outcome was the use of any AAT, including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription. Results: We identified 177,529 patients (49.9% female, mean age 73.0 (SD13.0) years) with incident AF during 2010–2018. Except for AADs, the differences in AAT use were nonsignificant when patients were stratified according to the rural–urban classification system (urban vs. rural adjusted incidence rate ratios (aIRRs) with 95% CIs for any AAT 1.01 (0.99–1.03), AADs 1.11 (1.07–1.15), cardioversion 1.01 (0.98–1.03), catheter ablation 1.05 (0.98–1.12)). However, slightly higher use of all rhythm control modalities was observed in the highest urbanization degree tertile when compared to the lowest tertile (aIRRs with 95% Cis for any AAT 1.06 (1.03–1.08), AADs 1.18 (1.14–1.23), cardioversion 1.05 (1.02–1.08), catheter ablation 1.10 (1.02–1.19)). Conclusions: This nationwide retrospective cohort study observed that urban residence is associated with higher use of AADs in patients with incident AF. Otherwise, the observed disparities were only marginal, suggesting that in the use of rhythm control therapies, no large rural–urban inequity exists in Finland.
No takes yet. Share an insight, caveat, or question.
Teppo et al. (2022) conducted a cohort in Incident atrial fibrillation (n=177,529). Urban residence vs. Rural residence was evaluated on Use of any antiarrhythmic therapy (AAT), including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription (aIRR 1.01, 95% CI 0.99-1.03). Urban residence compared to rural residence showed no significant difference in the overall use of any antiarrhythmic therapy among patients with incident atrial fibrillation (aIRR 1.01, 95% CI 0.99-1.03), suggesting no large geographic inequity in rhythm control strategy utilization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: